Browse Articles

Discover research articles across all indexed journals

Differences in health-related quality of life between rural and urban bladder cancer patients following radical cystectomy.

Journal of Clinical Oncology Thilo Westhofen, Alexander Buchner, Gerald Bastian Schulz et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.766

766 Background: Bladder cancer (BC) patients from rural areas (RA) may have more difficult access to health care with potentially detrimental impact on oncological outcome following radical cystectomy (RC). However, little is known on differences in health-related quality of life (HRQOL) between rural- and urban residents treated with RC for BC. We therefore aimed to assess these differences between rural and urban BC-patients by providing HRQOL data from a large prospective cohort of patients undergoing RC with a systematic follow-up of up to 10 yrs. Methods: n=1514 consecutive patients [n=576 from urban areas (UA), n=938 from rural areas (RA)] who underwent RC at a large tertiary care center were included. Exclusion criteria encompassed age <30 yr and RC due to benign diseases. HRQOL was assessed preoperatively, at 3 months, then annually until a maximum follow-up of 120 months, applying the validated EORTC QLQ-C30- as well as the bladder cancer-specific QLQ-BLM30- and FACT-BL-questionnaires. Separate modeling of longitudinal HRQOL for rural- and urban patients was performed. Spearman’s rank correlation was applied to identify residential-specific factors influencing HRQOL. Results: At baseline rural- and urban residents showed no significant difference in general HRQOL assessed by the global health status domain (GHS) (p=.983). In line no differences regarding symptom-related subscales were observed between both cohorts (p-range: .189 - .907). Postoperatively and in longitudinal analysis, rural residents reported significantly better general HRQOL up to 96 months after RC (p-range: .001 - .037). At 12 months, a significant correlation between physical-, emotional functioning or urinary continence and better general HRQOL was observed for both, rural- and urban residents (each p< .001). No significant correlation was found between sexual functioning and increased general HRQOL. While a significant correlation between Social/Family wellbeing and increased general HRQOL was found for rural residents (p=.042), no correlation was found for urban residents (p=.594). Conclusions: The current study provides prospective data from a contemporary cohort of BC-patients, which display residential-specific differences in the natural course of HRQOL following RC. Those results are important to guide individualized treatment decision-making for patients with BC.

Comprehensive modalities of kidney-sparing treatment in a carefully selected cohort of localized high-risk upper tract urothelial carcinoma: A potential paradigm shift.

Journal of Clinical Oncology Zeyu Chen, Jianjun Ye, Xiang Tu et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.794

794 Background: This study aims to assess the efficacy and safety of comprehensive modalities of kidney-sparing treatment in a carefully selected cohort of patients with localized high-risk upper tract urothelial carcinoma (UTUC). Methods: This study was initiated in January 2019 and is ongoing. Selected localized high-risk UTUC patients, characterized by conditions such as solitary kidney, bilateral tumors, impending renal insufficiency or patient refusal/ineligibility for radical nephroureterectomy (RNU), were included. Systemic therapy regimens were tailored to patient characteristics, tumor pathology and biomarkers, and included platinum-based chemotherapy, Disitamab Vedotin, and immune checkpoint inhibitors (ICIs). After endoscopic biopsy and attempted laser ablation, patients received four cycles of systemic induction therapy, followed by maximal endoscopic laser ablation or segmental ureterectomy. Postoperatively, a one-year course of immunotherapy maintenance was administered. The co-primary endpoints were disease-free survival (DFS) and conversion-free survival (CFS). Secondary endpoints included metastasis-free survival (MFS), renal function changes, ureteral stricture and treatment safety. Results: 68 patients were enrolled, with a follow-up of 18 months. 54 patients underwent endoscopic thulium laser tumor ablation, while 14 underwent segmental ureterectomy. The induction therapy comprised Disitamab Vedotin for 32 patients, platinum-based chemotherapy for 9, and immunotherapy for 37. Urothelial tract recurrence was observed in 28 patients with a 1-yr DFS rate was 58.82%, who subsequently underwent repeat endoscopic laser ablation. Salvage RNU was performed in 9 patients, yielding a 1-yr CFS rate of 93.7% and a 2-yr CFS rate of 88.9%. No distal metastasis was reported. Postoperative renal function impairment was noted in 15 patients (22.06%). Mean eGFR improvements were observed at various time points: 3.15 ml/min/1.73m 2 at 1 months, 5.07 ml/min/1.73m 2 at 3 months, 2.41 ml/min/1.73m 2 at 6 months, and 3.97 ml/min/1.73m 2 at 12 months. Ureteral stricture on the affected side was a common complication, which was more likely to occur in patients who underwent 3 or more times of ureteroscopy (9/27). Notably, no grade 3 or higher systemic toxicities were observed. Conclusions: Preliminary findings indicate that our comprehensive modalities of kidney-sparing treatment demonstrated promising tumor control and satisfactory renal function preservation in a carefully selected cohort of localized high-risk UTUC. Its definite application strategy and value should be further evaluated in future clinical practice.

Impact of deferred cytoreductive nephrectomy in the era of the immunotherapy in metastatic renal cell carcinoma: A multicenter retrospective study.

Journal of Clinical Oncology Patricia Rioja, Carolina Passarella, Martin Angel et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.502

502 Background: Deferred cytoreductive nephrectomy (dCN) is an emerging, strategy in the management of metastatic renal cell carcinoma (mRCC), applied selectively to patients who demonstrate a favorable response to initial systemic therapy. This study aimed to assess the clinical impact of dCN within the context of sequential treatment management. Methods: A multi-institutional retrospective evaluation. The descriptive analysis was performed to examine the demographic and clinical characteristics. Progression-free survival (PFS) and overall survival (OS) were analyzed by the Kaplan-Meier method. A level of p < 0.05 was considered significant. Results: With a median follow-up of 19 months (1-174 months), 50 patients were divided into three groups: 46% received IO+TKI, 24% received IO+IO, and 30% received TKI. Of the cohort, 66% were male, with median age of 60.6 years. All had clear cell histology, and 76% were intermediate IMDC risk. The most common metastatic sites were lungs (50%), lymph nodes (36%), and bone (32%). The median time from systemic therapy to cytoreductive nephrectomy (CN) was 6 months. Notably, 26% did not restart treatment post-CN, and 6% discontinued pre-CN (two due to toxicity, one due to progression). Median PFS was 36 months, with a 5-year PFS rate of 40%. Analysis by IMDC risk and type of treatment showed no significant differences. However, patients with a Karnofsky score (KS) ≤80% had a lower risk of progression than those with KS >80% [HR: 0.31, 95% CI (0.13-0.75), p=0.01] and those achieving complete response had a significantly lower risk of progression [HR: 8.59, 95% CI (1.1-67), p=0.042]. Median OS was 91 months, with no significant differences between groups. Conclusions: This study demonstrates that dCN can offer a therapeutic advantage especially in selected patients who achieve favorable responses to upfront systemic therapy. Careful patient selection is crucial to maximize the potential benefits of delayed surgery, reduce perioperative risks and improve oncological outcomes. Larger patient cohorts and well-designed prospective clinical trials are essential to solidify these findings and establish evidence-based guidelines.

Assessing the impact of PTEN loss on outcomes in high-/very high-risk, advanced hormone-sensitive prostate cancer patients: Institutional retrospective study.

Journal of Clinical Oncology Tamara Jamaspishvili, Palak Patel, Mackenzie Bennett et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.260

260 Background: Inactivation of tumor suppressor gene, PTEN (Phosphatase and tensin homolog) by deletion or mutation occurs in between 15-20% of localized prostate cancers and up to 50% of castration-resistant prostate cancers. The series of studies has shown a robust correlation between the genomic loss of PTEN and its protein as assessed by immunohistochemistry (IHC). Dysregulation of PI3K/AKT/mTOR signaling pathway has been linked with adverse pathological features and poor oncological outcomes such as the development of disease recurrence, metastasis, and castrate-resistant prostate cancer (CRPC). Here, we aim to study the prognostic and predictive role of PTEN in relation to treatment outcomes in a newly developed retrospective institutional research cohort. Methods: The cases with genomic PTEN loss (FoundationOne CDx, n=190) and protein loss by IHC (BenchMark Ultra, Roche Diagnostics, n=273) were pooled together. A total of 311 patients (PTEN loss=84, PTEN intact=227) that had available clinical and pathological information, including follow-up, were used for downstream statistical analysis. Kaplan-Meier analyses and univariate and multivariate Cox proportional hazard models were used to assess the benefit of RP over definitive RT with or without androgen deprivation therapy (ADT) for high-risk localized cohort as well as the benefit of primary ADT with or without intensification in the patients experiencing the loss of PTEN. Results: Patients with PTEN loss were more likely to present with advanced-stage disease (Stage IV: 33% vs. 19%) and more frequently received RT+ADT (43% vs. 34%) in high-risk patients. In contrast, those with intact PTEN were more likely to undergo radical prostatectomy (34% vs. 28%). Although overall survival (OS) did not differ significantly between all groups (log-rank p=0.51), mortality was higher in the PTEN loss group (32% vs. 22%). There was also a trend toward earlier development of castration-resistant prostate cancer (CRPC) in patients with PTEN loss (log-rank p=0.16). Conclusions: PTEN loss in prostate cancer is linked to more aggressive disease, higher mortality, and earlier CRPC development, consistent with existing literature. Our findings suggest that high-risk/very high patients with PTEN loss may benefit from definitive RT-based treatment over surgery. The study is limited by its retrospective, smaller sample size and single-institution design.

Simultaneous profiling of chromatin-associated RNA at targeted DNA loci and RNA-RNA Interactions through TaDRIM-seq

Nature Communications Cheng Ding, Guoting Chen, Shiping Luan et al. Feb 10, 2025 DOI: 10.1038/s41467-024-53534-5

Impact of public versus non public insurance on hispanic kidney transplant outcomes using UNOS database

Scientific Reports Charat Thongprayoon, Oscar A. Garcia Valencia, Caroline C. Jadlowiec et al. Feb 10, 2025 DOI: 10.1038/s41598-025-88672-3

Prognostic impact of first-line (1L) chemotherapy cycles in patients with metastatic urothelial carcinoma receiving avelumab 1L maintenance.

Journal of Clinical Oncology Satoshi Katayama, Tatsuhi Kawada, Keita Kobayashi et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.725

725 Background: First-line chemotherapy with 4-6 cycles followed by avelumab 1L maintenance therapy is the standard of care in patients with metastatic urothelial carcinoma (mUC). However, a non-negligible number of patients received less than four cycles of chemotherapy due to adverse events, or pre-existing severe comorbidities in our daily practice. Thus, we examined the prognostic impact of the number of first-line chemotherapy cycles in mUC patients treated with avelumab. Methods: In this multi-institutional study, we collected data of 91 patients with mUC who received avelumab maintenance therapy following 1 st -line chemotherapy. Patients were divided into those who received less than four cycles and those more than four cycles. Kaplan-Meier curve and Cox regression model were used to assess the association of chemotherapy cycles with overall (OS), cancer-specific (CSS), and progression-free survival (PFS). Logistic regression analyses were used to assess factors predicting initial progressive disease (PD). Results: Of the patients, 17 (19%) underwent less than four cycles of chemotherapy. Baseline characteristics, including chemotherapy regimen and best response to 1L chemotherapy, were comparable between the groups. Kaplan-Meier curve showed that patients receiving less than four cycles of chemotherapy were significantly associated with shorter OS ( p =0.032). On multivariable analyses controlling for the effects of confounding factors, the number of cycles (< 4) remained associated with worse OS, CSS, and PFS (HR 2.83; 95%CI 1.32-6.08; p=0.008, HR 3.37; 95%CI 1.52-7.47; p=0.003, and HR 2.11; 95%CI 1.09-4.07; p=0.03, respectively). In addition, the number of cycles was associated with an increased risk of initial PD (OR 3.26; 95%CI 1.08-9.79; p =0.035) for avelumab maintenance therapy. Conclusions: The inadequate number of 1L chemotherapy cycles was associated with poor survival outcomes and was at an increased risk of initial PD in patients receiving avelumab maintenance therapy. More than four cycles of 1L chemotherapy should be given to ensure the efficacy of avelumab maintenance therapy in patients with mUC.   OS CSS PFS Predicting PD Multivariable Multivariable Multivariable   Multivariate     HR (95% CI) P value   HR (95% CI) P value   HR (95% CI) P value   OR (95% CI) P value Age (ref. < 70) 1.2 0.54-2.70 0.66 1.09 0.48-2.49 0.84 1.21 0.46-3.23 0.70 1.54 0.48-4.96 0.47 ECOG-PS≥2 (ref.≤1) 7.01 1.67-29.9 0.008 10.3 2.27-46.9 0.003 2.63 0.29-23.7 0.39 1.07 0.10-11.3 0.96 Severe AE (ref. < G3) 0.96 0.47-1.94 0.9 0.80 0.38-1.66 0.55 1.86 0.83-4.15 0.13 Visceral metastasis 2.20 1.05-4.60 0.037 2.43 1.11-5.29 0.026 2.23 1.01-4.91 0.046 eGFR (ref. < 60) 0.81 0.34-1.89 0.62 0.70 0.28-1.75 0.44 0.62 0.22-1.77 0.38 1st-line chemotherapy cycle (ref. ≥ 4)   2.83 1.32-6.08 0.008   3.37 1.52-7.47 0.003   2.11 1.09-4.07 0.03   3.26 1.08-9.79 0.035

Identification of potential immune evasion mechanisms in aggressive small renal cell carcinomas through single-cell and bulk RNA sequencing.

Journal of Clinical Oncology Jee Soo Park, Eun Chae Kim, Seol Song et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.574

574 Background: Small renal cell carcinoma (RCC) is generally nonaggressive but in some cases, small RCCs exhibit distant metastasis. The biology and biomarker of small aggressive RCCs remain unclear, necessitating appropriate evaluation to avoid undertreatment. Previous biomarker studies via genetic profiling of tumor tissues were hindered by RCC heterogeneity. We utilized bulk RNA sequencing and single-cell RNA sequencing (scRNA-seq) of blood samples to identify genetic biomarkers and characterize the tumor immune microenvironment in patients with aggressive small RCC. Methods: We identified four T1a (≤4 cm) clear cell RCCs (ccRCC) with synchronous distant metastasis as aggressive, and four age-, sex-, and tumor size-matched ccRCC patients without metastasis as non-aggressive, from a prospective cohort (ClinicalTrials.gov Identifier: NCT03694912). Two healthy kidney donors served as controls. Using the 10X Genomics platform, we performed scRNA-seq and bulk analysis on ten peripheral blood mononuclear cell (PBMC) samples. Samples were demultiplexed with Souporcell, and sequencing reads were normalized and analyzed using R/Seurat. Cellular components were identified with marker genes, and bulk analysis included differential gene expression and pathway enrichment. Results: The mean tumor size and age of the eight ccRCC patients were 2.5 cm and 63 years, respectively. Among the four aggressive ccRCCs, two had lung metastasis and two had bone metastasis. We analyzed 32,417 cells, identifying 41 subpopulations. Single-cell analysis revealed variations in T and natural killer (NK) cell proportions among aggressive, non-aggressive, and normal groups, with significant differences. The aggressive group showed increased MYOM2, OVCH1-AS1, and HLA-DQA2 expression. Despite an increased proportion of CD4+ cytotoxic T lymphocytes (CTLs) with disease severity, key cytotoxic and immune regulatory genes like GNLY, CD247, CCL4, NKG7, and TGFB1 were decreased, suggesting compromised antitumor function in aggressive states. Conclusions: This study offers insights into the molecular and cellular characteristics of aggressive small RCCs via PBMC analysis using single-cell and bulk RNA sequencing. The increased proportion of CD4+ CTLs with decreased expression of critical cytotoxic and immune regulatory genes in aggressive RCCs suggests a mechanism for immune evasion. These findings enhance our understanding of aggressive small RCC biology and highlight potential biomarkers and therapeutic targets for adjuvant treatment. Clinical trial information: NCT03694912 .

Role of circulating tumor DNA (ctDNA) in locally advanced (LA) and metastatic urothelial cancer (mUC).

Journal of Clinical Oncology Minira Aslanova, Arianna Lawrence, Hongkun Wang et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.685

685 Background: The role of ctDNA is emerging as an adjunctive prognostic tool for survival in the laUC setting, but its role is evolving in mUC. We aimed to analyze ctDNA in the real-world setting and correlate its trend with available clinical, radiographic, and next generation sequencing (NGS) data. Methods: Patients with a diagnosis of laUC and mUC were included in the analysis of an IRB-approved protocol. Clinical/pathologic stage, systemic therapy received, NGS (TEMPUS) results, and tumor-informed detection and quantification (Signatera, Natera, Inc) was analyzed with baseline ctDNA data (positive + vs. negative -). Mean tumor molecules (MTM) levels were obtained and time to radiographic progression (TTrP), radiographic progression-free survival (rPFS) and overall survival (OS) evaluated. If baseline ctDNA was negative (ctDNA-), time to initial ctDNA+ was recorded. Analyses of time in days (d) from ctDNA- to ctDNA+ with regard to radiographic progression and OS was analyzed using Kaplan-Meier method and between group comparison by Log-rank test. Descriptive statistics were used to evaluate ctDNA trends in patients receiving various systemic therapies. Results: 47 patients (n=24 laUC; n=23 mUC) were included in analyses; 34 Male, 14 Female. The median rPFS in patients with baseline ctDNA+ was 189d. Higher baseline levels did not significantly affect rPFS (p=0.0518, HR=1.007) or TTrP (p=0.2718, HR=1.004). The median rPFS in baseline ctDNA- level was 553d. The overall TTrP was worse in mUC baseline ctDNA+ vs baseline ctDNA- (log-rank p=0.037). Median OS in baseline ctDNA+ was 266d and ctDNA- was not evaluable. Patients who received immunotherapy-based treatment or antibody-drug-conjugate based therapy had a decline in baseline ctDNA at 1 month follow up. Lack of response or clearance of ctDNA served as predictor of mortality. Of the mUC patients who had baseline ctDNA +, mortality was as high as 70% at the time of follow up. No correlation with specific NGS findings were seen. Conclusions: The use of ctDNA allowed for identification of earlier disease relapse than radiographic imaging alone which allows for earlier switch in therapeutic management. Obtaining a baseline positive ctDNA result without conversion to a negative value portends a poor prognosis in mUC.

Efficacy and safety of fexagratinib (Fexa) in combination with tislelizumab (T) in a phase II study of patients (pts) with locally advanced or metastatic urothelial carcinoma (mUC) harboring FGFR alterations (FGFRa).

Journal of Clinical Oncology Xiaojie Bian, Dingwei Ye, Lijun Chen et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.789

789 Background: A significant proportion of pts with mUC are intolerant to platinum-based chemotherapy, highlighting the urgent need for alternatives. Fexagratinib(former AZD4547)is a potent and selective inhibitor of FGFR and had showed promising anti-tumor activity in mUC pts with FGFRa. This Phase II study (NCT05775874) aimed to evaluate efficacy of Fexa plus T combination treatment (Tx) in mUC pts harboring FGFRa who were 1st-line platinum-ineligible or rejected chemotherapy. Methods: FGFR3 mRNA overexpression were detected by in situ hybridization (RNAscope). FGFR3 activating mutations or fusions were detected by NGS. Eligible pts received continuous oral Fexa 80mg BID plus T 200 mg infusion on day 1 of a 21-day cycle. Primary objectives were objective response rate (ORR) by Independent Review Committee (IRC) per RECIST 1.1. Results: As of data cut off (10 Aug 2024), 26 pts received combination Tx with the majority being treatment-naïve. Of those, 57.7% were male with median age of 68.5 years and 86% had an ECOG of 1. Nine pts had confirmed FGFR3 mutation or fusion and 24 pts were overexpression. In 22 pts with available PD-L1 expression status, 86.4% were negative (CPS<10). Among 24 IRC evaluable pts, 9 (37.5%) partial responses (PRs) were confirmed. The median duration of response was 5.9 months. The median progression free survival mPFS was 5.3 months (95%CI 2.7-8.2) with 4 pts were still on Tx. Among the evaluable pts with FGFR3 overexpression but without mutation/fusion, ORR was37.5%,(6/16)pts.Most common treatment-related adverse events (TRAEs) were stomatitis (42%), anemia (38.5%), AST/ALT increased (27%). Grade ≥3 TRAEs occurred in 12 (46.2%) pts, incidence >10% events included stomatitis (n=3, 12%), hand-foot syndrome(n=3, 12%). Immune-related AEs occurred in 23.0% of pts. The majority of TRAEs were reversible. Conclusions: 1st-line Tx with Fexa plus T were tolerable with a safety profile consistent with previously reported for both agents. The toxicity was overall manageable. Encouraging efficacy was observed in pts with FGFR3 overexpression, regardless of PD-L1 expression or FGFR3 mutations/fusions.Further exploration of these findings is warranted. Clinical trial information: NCT05775874 .

Visualization of chromosomal reorganization induced by heterologous fusions in the mammalian nucleus

Nature Communications Meng Yan, Xiaoyu Merlin Zhang, Zhenhua Yang et al. Feb 10, 2025 DOI: 10.1038/s41467-024-55582-3

Small-world networks propensity in spontaneous speech signals of Alzheimer’s disease: visibility graph analysis

Scientific Reports Mahda Nasrolahzadeh, Zeynab Mohammadpoory, Javad Haddadnia Feb 10, 2025 DOI: 10.1038/s41598-025-88947-9

The analysis of active surveillance for Japanese young early-stage prostate cancer patients: From the PRIAS-JAPAN study.

Journal of Clinical Oncology Takuma Kato, Takahiro Kimura, Ryuji Matsumoto et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.351

351 Background: The current status of active surveillance (AS) for early-stage young Japanese patients is unknown. We examined it from the data of PRIAS-JAPAN, a multicenter prospective collaborative study of AS in Japan. Methods: Initially, low-risk patients with a PSA density (PSAD) <0.2 and 2 or fewer positive cores were eligible. The eligibility criteria have since been revised accordingly, and from 2021, when MRI imaging was performed, the inclusion criteria allowed a PSAD of up to 0.25, no upper limit on the number of positive cores for Gleason score (GS) 3+3 cases, and up to half of the total number of positive cores for intermediate-risk GS 3+4 cases. PSA test every 3 months, rectal examination every 6 months, biopsy at 1, 4, 7, and 10 years, and every 5 years after that, and recommendation for secondary treatment after confirming pathological deterioration. The AS results and clinical outcomes were compared between the patients aged 60 years and younger (Young group: Y-group, n=165) and those over 60 years old (elderly group: E-group; n=1,109). Results: In the Y-group, the median age was 57 years, the median PSA at diagnosis was 4.8 ng/ml, the median prostate volume was 33.4 cm3, the median PSAD was 0.15 ng/ml/c m3,T1c was 149. At diagnosis, the Y-group had significantly smaller prostate volumes and a higher proportion of GS 3+3 cases than the E-group. The biopsy acceptance rate decreased with increasing (1 st , 2 nd , 3 rd, and 4th year: 81.8%, 70.3%, 34.4%, and 13.3%). The reclassification rate increased over time (1 st , 2 nd , 3 rd and 4th year: 28.7%, 30.8%, 27.3%, and 50.0%). The persistence rate of the Y-group decreased over time, with a 10-year persistence rate of 19.2%, with no significant difference between the two groups. The 10-year metastasis-free survival (MFS), 10-year overall survival (VS), and 10-year cancer-specific survival (CSS) rates of the Y-group were 98.8%, 98.9%, and 100%, respectively. Although OS was lower in the Y-group (p=0.051, HR=2.29. 95%CI 1.004-5.21), MFS and CSS did not significantly differ between the two groups. The Y-group was more likely than the E-group to choose prostatectomy (38.3%) as the next treatment, while they did not want hormone therapy (4,7%) or watchful waiting (6.5%). Conclusions: Although the Y-group was superior to the E-group in OS, there was no significant difference in MFS and CSS between the two groups. AS persistence rate Metastasis-free survival   3 year 5 year 10 year 13 year   3 year 5 year 10 year 13 year ≤60y.o 55.7% 39.9% 19.2% 17.1% ≤60y.o 100% 100% 99% 99% 60y.o< 58.2% 38.5% 16.3% 12.0% 60y.o< 100% 100% 99% 98% Overall survival Cancer-specific survival   3 year 5 year 10 year 13 year   3 year 5 year 10 year 13 year ≤60y.o 100.0% 100.0% 98.9% 95.3% ≤60y.o 100.0% 100.0% 100.0% 100.0% 60y.o< 97.9% 97.0% 92.2% 88.7% 60y.o< 99.9% 99.9% 99.9% 99.9%

Impact of PSMA-PET and conventional imaging on contemporary management in patients with biochemical recurrence after radical prostatectomy.

Journal of Clinical Oncology Arielle Ilano, Lufan Wang, Janet E Cowan et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.43

43 Background: Prostate-specific membrane antigen (PSMA) PET imaging is recommended for patients with biochemical recurrence (BCR) after radical prostatectomy (RP). This study describes the early clinical impact of PSMA-PET compared to conventional imaging (CT, MRI, or bone scintigraphy) in a contemporaneous period. Methods: This retrospective study includes patients with BCR after RP (defined as PSA≥0.2 after undetectable PSA post-operatively) who underwent PSMA-PET or conventional imaging (CI) between 2010-2023. The primary outcome was positive detection rate. The secondary outcomes were rates of salvage treatment (XRT±ADT) and second BCR. Cox proportional hazards modeling was used to predict risk of salvage treatment and second BCR. Results: 217 post-RP patients were included. Of the 146 patients who underwent PSMA-PET and the 71 who underwent CI, 77 (52.7%) and 7 (9.9%) patients had positive imaging findings at a median PSA value of 0.23 (IQR 0.21-0.33) and 0.25 (IQR 0.25-0.44), respectively (p=0.36). 48 patients received both imaging modalities; 4 had positive results in both PSMA-PET and CI, while 26 were positive for PSMA-PET only, and 2 were positive on CI only. Patients underwent salvage therapy at lower median PSA values in the PSMA-PET group (0.40 vs 0.51, p<0.01). On unadjusted survival analysis, there were no differences in salvage therapy rates or second BCR rates between PSMA-PET or CI groups. On multivariable Cox proportional hazards modeling, year of PSA recurrence (HR 0.89, 95% CI 0.84-0.95), BMI (HR 1.45, 95% CI 1.02-2.07), ≥GG3 (HR 1.77 95% CI 1.3-2.4), and undetectable PSA≥6 months after RP (HR 0.50 95% CI 0.34-0.72) were associated with salvage treatment, but imaging modality was not. High genomic risk scores (Decipher>0.60) may be associated with second BCR (HR 2.03 95% CI 0.99-4.18, p=0.05) while other variables were not. Conclusions: PSMA-PET usage increased over the period of this study with higher sensitivity at lower median PSA at BCR. Imaging modality did not predict rates of salvage therapy or second BCR, while other clinical risk factors such as adverse pathology and high genomic risk score did. Analysis with a historical cohort is pending.

Epigenomic profiling of circulating chromatin for early detection and monitoring of neuroendocrine prostate cancer.

Journal of Clinical Oncology Karl Semaan, Rashad Nawfal, Marc Eid et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.253

253 Background: Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of prostate cancer that can arise after androgen blockade. Early detection of NEPC has prognostic and therapeutic implications but remains challenging. Neuroendocrine (NE) transformation is spatially heterogeneous, with co-existing NE and adenocarcinoma (AD) components across a patient's disease burden, leading to underdiagnosis using tumor biopsy. Moreover, treatment response assessment with cross-sectional imaging cannot distinguish changes in co-existing NE and AD components. To address these challenges, we developed a non-invasive approach to monitor NE transformation in patients with prostate AD (PRAD) through profiling of circulating chromatin. Methods: Plasma samples were collected longitudinally from patients initially diagnosed with PRAD who later developed NEPC at the Dana-Farber Cancer Institute. Chromatin immunoprecipitation and sequencing on cell-free DNA (cfChIP-seq) was performed for H3K27ac, a histone modification enriched at active promoters and enhancers. To separately quantify circulating chromatin derived from NE and AD components in a given patient, we measured H3K27ac at NE-specific enhancers (NE-score) and androgen receptor binding sites (AD-score), respectively. Whole genome sequencing was performed to estimate the cfDNA tumor fraction (TF) using ichorCNA. To evaluate cfChIP-seq for monitoring NEPC treatment response, we calculated changes in NE-score and TF for each pair of consecutive plasma draws after NE transformation. We then compared these changes during intervals of disease progression, stability, or response using the Kruskal-Wallis test. Results: This study included 32 plasma samples from 5 patients, with 14 pre-NE and 18 post-NE diagnosis, collected between December 2016 and April 2022. The NE-score was significantly elevated in post-NE compared to pre-NE samples (Wilcoxon sum rank p<0.01). NE-scores between consecutive draws increased at times of disease progression, changed minimally with disease stability, and decreased during response (median change: 16 vs. 2.0 vs. -32%, resp.; p=0.035). Importantly, changes in TF, which reflects an aggregate of AD and NE-derived tumor DNA, were less pronounced (11 vs. -0.5 vs. -13%, resp.; p=0.3). The AD-score was positively correlated with PSA levels (R=0.59; p<0.001). In 2 patients with plasma collected within 3 months prior to NE transformation, NE scores increased prior to pathologic diagnosis of NEPC. Another case revealed an increase in AD-score and PSA accompanied by a decrease in NE-score when a patient stopped ADT and started platinum-based chemotherapy for NEPC. Conclusions: Epigenomic profiling of circulating chromatin may enable early detection of NEPC and monitoring of NE and AD components in metastatic prostate cancer.

SUBDUE-3: Sub-urothelial durvalumab-sirconium to investigate local and systemic distribution of durvalumab when injected in the sub-urothelium.

Journal of Clinical Oncology Kevin Keane, Andrisha Jade Inderjeeth, Roslyn J. Francis et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps903

TPS903 Background: Sub-urothelial injection of durvalumab presents a novel therapeutic approach for bladder cancer. SUBDUE-1, a first-in-human Phase Ib dose escalation study presented at ASCO 2022, demonstrated the safety and tolerability of sub-urothelial durvalumab in patients with bladder cancer scheduled for radical cystectomy, with no treatment-related adverse events and preliminary evidence of immunomodulation in the tumour microenvironment 1 . SUBDUE-3 will use radiolabelled 89 Zirconium-durvalumab ( 89 Zr-durvalumab) to define local and systemic biodistribution following sub-urothelial injection. Methods: SUBDUE-3 is an open-label, non-randomized Phase 0 trial sponsored by ANZUP (ANZUP 2402, ACTRN 12624001245583p). Ethics approval has been obtained for this study which is currently recruiting patients diagnosed with either high-risk non-muscle-invasive bladder cancer (HR-NMIBC) or muscle-invasive bladder cancer (MIBC), scheduled for radical cystectomy. 25mL of sub-urothelial 89 Zr-durvalumab will be injected in 1mL aliquots throughout the bladder using a 5Fr Bonee needle via 22Fr rigid cystoscope at a GA cystoscopy performed 2 weeks pre-cystectomy. After injection, PET imaging will be performed at several time points over 7 days. At each imaging time point, blood samples will be collected to evaluate the systemic bioavailability of 89 Zr-durvalumab using a gamma counter. Additionally, the urinary radiation dose will be measured during the first imaging session. Quality control measures will assess dissociation of 89 Zr from durvalumab. Dosimetric analyses will determine the distribution and radiation dose of 89 Zr-durvalumab both within the bladder and systemically, providing critical insights for future therapeutic strategies in bladder cancer treatment. Primary endpoint: visual and semi-quantitative assessment of 89 Zr-durvalumab distribution within the bladder wall and systemic organs (liver, kidney, lung, bone marrow) via PET imaging. Secondary endpoints: bladder and other organ tracer biodistribution; comparison of dosimetry data with cohorts receiving systemic 89 Zr-durvalumab; safety; feasibility. The trial has a one-year recruitment strategy aiming to recruit up to 3 patients and is expected to finish recruiting in 2025. References: 1. Hayne D. Et al. The SUB-urothelial DUrvalumab InjEction-1 (SUBDUE-1) trial: first-in-human trial in patients with bladder cancer. BJU Int. 2024 Aug;134(2):283-290. doi: 10.1111/bju.16325. Epub 2024 Mar 12. PMID: 38469652. Clinical trial information: ACTRN 12624001245583p.

Regorafenib plus sintilimab as a salvage treatment for microsatellite stable metastatic colorectal cancer: a single-arm, open-label, phase II clinical trial

Nature Communications Rui Liu, Zhi Ji, Xia Wang et al. Feb 10, 2025 DOI: 10.1038/s41467-025-56748-3

Mapping of regions with low tuberculosis notification and estimation of diagnostic gaps in Cameroon, evidence from OpenStreetMap and WorldPop data

Scientific Reports Christelle Geneviève Jouego, Titahong Nosoh Collins, Bryan Tegomoh et al. Feb 10, 2025 DOI: 10.1038/s41598-025-87682-5

Adherence to clinical surveillance guidelines in von Hippel-Lindau (vHL) disease: Evaluating the impact of a coordinated care centre implementation in Canada.

Journal of Clinical Oncology Dawson Born, Anna Pasco, Maryam Soleimani Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.460

460 Background: VHL is a rare hereditary cancer syndrome, predisposing to the development of multiorgan tumour growth, including bilateral and recurrent clear cell renal cell carcinoma. While guidelines for the screening and management of these patients exist, adherence to guidelines is variable. The development of coordinated clinical care centres with multidisciplinary expertise in rare diseases has been demonstrated to improve outcomes. Methods: In this study, we reviewed adherence to surveillance guidelines prior to and after development of a Canadian provincial vHL clinic at our institution, British Columbia (BC) Cancer. Care in this clinic is provided both in-person and through telehealth. We sought to evaluate whether patient geographic distance from the clinic impacted time to being seen for consultation, and whether there was a change in management plan after being seen in the clinic. Results: Between June 2022, and April 2024, 57 patients were seen in the vHL clinic (median age 34, 58% female, and 42% male). Of these, 13 lived within 50km from the clinic, 7 within 50-100km, 8 within 100-500km, and 29 lived more than 500km away. We found significant improvement in adherence to nearly all surveillance guidelines after the development of the vHL Clinic (table). 10.5% of patients had never had germline confirmation of vHL and were referred for expedited testing after being seen. We did not find any difference in time from referral to consultation based on patient geographic proximity to the clinic, F(3,53)=1.10, p =0.35 nor the modality of initial consultation (t(55)=1.07, p =0.29; in person vs telehealth). Finally, after initial consultation, 87% of patients had a change in their management plans, most commonly involving referral for further subspecialty evaluation (n=41) or initiation of pharmaceutical treatment (n=24). Conclusions: Our results add to existing evidence that coordinated care centres with multidisciplinary expertise in vHL are feasible in the Canadian public healthcare system and can result in improvements in quality of care. Our clinic model has a robust multidisciplinary care team that utilizes technology to reach patients for equitable access to care. Future work will evaluate potential cost savings to the healthcare system with this model, as well as patient satisfaction with their care pre and post participation in the vHL clinic. Adherence to clinical screening guidelines for patients with vHL before and after consultation with the BC cancer provincial vHL clinic. Screening Guideline Parameter Pre connection with vHL clinic Post connection with vHL clinic Central nervous system imaging 51.8% 100%* Abdomen/Pelvis imaging 44.6% 100%* Metanephrines 8.9% 64.3%* Ophthalmologic 75.0% 85.7% Audiology 21.4% 85.7%* *Statistically significant difference ( p <0.05).

Who undergoes cytoreductive nephrectomy now? An analysis of perioperative risk characteristics in contemporary patients.

Journal of Clinical Oncology Shawn Dason, Rajvi R. Goradia, Akshay Sood et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.493

493 Background: Cytoreductive nephrectomy (CN) has traditionally been the first step in managing metastatic renal cell carcinoma (mRCC). However, the role of routine upfront cytoreductive nephrectomy in mRCC was questioned by the 2018 publications of CARMENA and SURTIME. That same year, Checkmate 214 highlighted the superior effectiveness of immune checkpoint inhibition as first-line systemic therapy in mRCC compared to sunitinib. IMDC risk assessment is widely used in mRCC decision-making. Data from the ACS-NSQIP, a validated method for assessing surgical risk, is commonly used to predict perioperative mortality and morbidity. We sought to understand how the risk characteristics of patients undergoing CN have changed since the reporting of CARMENA, SURTIME, and Checkmate 214 in 2018. Methods: This study used ACS-NSQIP data sets from 2015-2022. It included patients undergoing nephrectomy for mRCC with disseminated cancer, excluding those from 2018. Baseline characteristics and perioperative outcomes were compared using chi-square tests, t-tests, or logistic regression as appropriate. Data was available to approximate 3 of the 6 IMDC criteria (anemia, thrombocytosis, and performance status). Results: Of 82268 nephrectomies performed from 2015-2022, 2191 CN were appropriate for inclusion. The proportion of CN as a share of all nephrectomies in NSQIP has decreased since 2018 (Table, p<0.05). Similarly, the proportion of patients undergoing CN with at least 1, 2, or 3 IMDC criteria has also dropped (Table, p<0.05). The median NSQIP-predicted mortality and morbidity have significantly declined (Table, p<0.05). Assessment of 18 baseline characteristics revealed that no single factor could fully account for the observed risk differences. Since 2018, the median length of stay has reduced from 4 to 3 days, and the proportion of outpatient surgeries has risen from 2.6% to 6% (p<0.05). Despite variations in baseline risk, no significant differences were observed in mortality, major complications, operative characteristics, or readmission rates. Conclusions: Since 2018, patients undergoing CN have had lower IMDC and NSQIP risk profiles, and the overall number of CN procedures has declined. These shifts should be taken into account when interpreting historical data on CN. Further research is needed to assess whether this more selective approach to CN has resulted in improved outcomes since 2018. Characteristics of patients undergoing CN (all p<0.05). Characteristic Pre-2018 (n=1165) Post-2018 (n=1026) Cytoreductive nephrectomy / total nephrectomies in NSQIP during period 1165/32071 = 3.6% 1026/50197 = 2.0% Minimum IMDC Criteria* 0 50.0% 54.5% 1 39.1% 37.7% 2 10.2% 7.8% 3 0.7% 0% Predicted Mortality Median 1.5% 1.2% 90 th percentile 5.6% 4.8% Predicted Morbidity Median 10.3% 9.9% 90 th percentile 14.0% 12.3% *Only anemia, thrombocytosis, and performance status could be assessed.